Point Therapeutics Announces Results From Phase 2 Metastatic Melanoma Clinical Program At iSBTc Conference

BOSTON--(BUSINESS WIRE)--Nov. 11, 2005--Point Therapeutics, Inc. (NASDAQ: POTP) announced results in the company’s Phase 2 single-agent study of its oral anti-cancer drug candidate, talabostat, in patients with Stage IV melanoma. These results will be presented in a poster session at the International Society for Biological Therapy of Cancer meeting in Alexandria, VA on Saturday, November 12, 2005. The company’s metastatic melanoma clinical program also includes studying talabostat in a Phase 2 trial in combination with cisplatin.

MORE ON THIS TOPIC